Login to Your Account



ImmunoGen, Centocor Partner In Potential $43.5M TAP Deal

By Karen Pihl-Carey


Wednesday, December 29, 2004
ImmunoGen Inc. licensed certain rights to its Tumor-Activated Prodrug (TAP) technology to Centocor Inc. in a deal worth up to $43.5 million, plus royalties. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription